Published on 18 Apr 2023 on Simply Wall St. via Yahoo Finance
Investors Still Waiting For A Pull Back In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a stock to potentially avoid, seeing as almost half of all the Life Sciences companies in the United States have P/S ratios under 4.4x and even P/S lower than 2x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's as high as it is.
Check out our latest analysis for Adaptive Biotechnologies
